Tokyo, Japan

Mitsuhiro Yazawa

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):

Title: Mitsuhiro Yazawa: Innovator in Antibody Development

Introduction

Mitsuhiro Yazawa is a prominent inventor based in Tokyo, Japan. He is known for his significant contributions to the field of biotechnology, particularly in the development of antibodies that exhibit antitumor activity. His work has the potential to impact cancer treatment significantly.

Latest Patents

Yazawa holds a patent for an Anti B7-H3 antibody. This innovative antibody binds to B7-H3, a functional fragment of the antibody, and is part of a pharmaceutical composition that includes the antibody or its functional fragment. The patent also covers methods for making the antibody or the functional fragment, as well as methods for treating tumors using the antibody or its functional fragment. Additionally, it includes polynucleotides encoding the antibody or the functional fragment. He has 1 patent to his name.

Career Highlights

Mitsuhiro Yazawa is associated with Daiichi Sankyo Company, Limited, where he continues to advance his research in antibody development. His work at this esteemed company has allowed him to collaborate with other talented professionals in the field.

Collaborations

Yazawa has worked alongside notable colleagues such as Shu Takahashi and Tatsuji Matsuoka. Their combined expertise contributes to the innovative research and development efforts at Daiichi Sankyo.

Conclusion

Mitsuhiro Yazawa is a key figure in the development of therapeutic antibodies, with a focus on antitumor applications. His contributions to the field are paving the way for new cancer treatments and showcasing the importance of innovation in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…